Skip to main content
Haisco Pharmaceutical Group Co.,Ltd logo

Haisco Pharmaceutical Group Co.,Ltd — Investor Relations & Filings

Ticker · 002653 ISIN · CNE100001BC7 LEI · 300300GRLH34A8GPJ639 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,439 across all filing types
Latest filing 2025-02-27 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 002653

About Haisco Pharmaceutical Group Co.,Ltd

https://www.haisco.com

Haisco Pharmaceutical Group Co.,Ltd. focuses on the research, development, production, and commercialization of innovative drugs and high-end generic pharmaceuticals. The company maintains a specialized portfolio across therapeutic areas including anesthesia, parenteral nutrition, anti-infection, cardiovascular health, and endocrine disorders. Key products include advanced anesthetic agents and specialized nutritional injections designed for clinical use. Haisco prioritizes technological innovation through a dedicated R&D infrastructure, targeting the development of small molecule chemical drugs and complex delivery systems. Its operations emphasize high-standard manufacturing processes and the integration of clinical research to address complex medical requirements. The company aims to provide therapeutic solutions that enhance patient care through a commitment to scientific excellence and product quality.

Recent filings

Filing Released Lang Actions
关于2025年度向特定对象发行股票摊薄即期回报及采取填补措施和相关主体承诺的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement regarding a specific issuance of shares to particular investors, including the impact on financial metrics, risk disclosures, project descriptions, and commitments by company management and controlling shareholders. It discusses the dilution of immediate returns due to the issuance and the measures to compensate for this dilution. The document references regulatory guidelines and includes detailed financial assumptions and projections related to the issuance. It is not a full annual or interim report, nor is it a simple announcement of a report. It is a capital/financing update focused on a specific share issuance and related financial and operational impacts. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2025-02-27 Chinese
第五届监事会第十三次会议决议公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement of resolutions passed at the 13th meeting of the 5th Supervisory Board of Haishike Pharmaceutical Group Co., Ltd. The content focuses on the approval of a proposal for a targeted issuance of A-shares, including details on the issuance conditions, pricing, quantity, use of proceeds, lock-up period, and related reports. It is a formal meeting resolution announcement related to capital raising activities. The document does not contain financial statements or quarterly/yearly financial results but rather decisions and approvals related to a capital increase via share issuance. This fits the category of Capital/Financing Update (CAP), as it provides updates on company fundraising and capital structure changes. The document length is over 5,000 characters and contains substantive content, not just a brief announcement or a certification letter, so it is not RPA or RNS. Therefore, the correct classification is CAP with high confidence.
2025-02-27 Chinese
关于向特定对象发行股票不存在直接或通过利益相关方向参与认购的投资者提供财务资助或补偿的公告
Capital/Financing Update Classification · 95% confidence The document is a short announcement from the company Hai Si Ke Pharmaceutical Group Co., Ltd. regarding the issuance of A-shares to specific investors. It explicitly states that the company does not provide financial assistance or compensation to investors subscribing to the shares. The document is brief (444 characters) and focuses on a capital issuance matter without detailed financial data or comprehensive report content. It is not a full financial report but an announcement related to capital issuance. Therefore, it fits the category of Capital/Financing Update (CAP).
2025-02-27 Chinese
前次募集资金使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is a detailed report on the usage of previously raised funds by the company 海思科医药集团股份有限公司. It includes specifics about the amount raised, timing, management, actual usage, changes in usage, and economic benefits of the investment projects funded by the previous capital raise. It references regulatory approvals and audit reports related to the fundraising. The document is 7362 characters long, which is substantial and contains detailed financial and operational data about the use of raised capital. This matches the description of a Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes. It is not an announcement of a report but the report itself, and it is not a general regulatory filing or a certification. Therefore, the appropriate classification is CAP with high confidence.
2025-02-27 Chinese
未来三年（2025年-2027年）股东回报规划
Notice of Dividend Amount Classification · 85% confidence The document is a detailed plan outlining the company's shareholder return policy for the next three years (2025-2027), including principles, conditions for cash dividends, dividend ratios, decision-making procedures, and adjustment mechanisms. It is a forward-looking policy document related to dividends and shareholder returns rather than an announcement of dividend amounts or payment dates. It does not contain actual financial statements or results, nor is it a brief summary or presentation. It is not a regulatory announcement or a report publication notice. The content fits best with a Notice of Dividend Amount (DIV) category because it deals with dividend policy and shareholder returns over a defined period, which is typical for dividend-related filings. Although it is a planning document rather than a single dividend announcement, the closest specific category is DIV, as it relates to dividend distribution plans and policies.
2025-02-27 Chinese
关于暂不召开股东大会审议2025年度向特定对象发行股票相关事项的公告
Capital/Financing Update Classification · 95% confidence The document is a short announcement from the company Hai Si Ke Pharmaceutical Group Co., Ltd. stating that the board has decided not to convene a shareholders' meeting to review the 2025 specific object stock issuance matters at this time. It mentions that the board meeting approved the proposal and that the shareholders' meeting will be scheduled later. The document is only 484 characters long and serves as a notification about the postponement of the shareholders' meeting related to a capital issuance. It does not contain financial data, detailed report content, or voting results. It is an announcement about capital raising activities but not the actual update or report on financing. According to the definitions and rules, this fits best under Capital/Financing Update (CAP) as it relates to the company's financing activities and capital structure changes, specifically the issuance of shares to specific investors. The document is not a full report, not a voting result, and not a regulatory filing or report publication announcement. Therefore, the classification is CAP with high confidence.
2025-02-27 Chinese

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.